Atlas Trials

Fibroblast Specific Inhibition of LOXL2 and TGFbeta1 Signaling in Patients With Pulmonary Fibrosis.

Clinical trial NCT03928847 · COMPLETED

Trial details

NCT number
NCT03928847
Sponsor
Hal Chapman
Status
COMPLETED
Phase
Early Phase 1
Study type
INTERVENTIONAL
Idiopathic Pulmonary Fibrosis
Start date
2017-12-01
Primary completion
2019-05-31
Enrollment
35

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.